| PRECIGEN INC. |
| USA |
| Gesundheit |
| US74017N1054 / A2PZG1 |
| I5X (Frankfurt) / PGEN (NASDAQ) |
| FRA:I5X, ETR:I5X, I5X:GR, NASDAQ:PGEN |
| - |
| https://precigen.com/ |
|
Precigen Inc. is a discovery and clinical-stage biopharmaceutical company focused on developing gene and cell therapies using precision technology to address diseases in immuno-oncology, autoimmune disorders, and infectious diseases. The company oper..
>Volltext.. |
| 1128.76 Mio. EUR |
| 1129.13 Mio. EUR |
| 8.42 Mio. EUR |
| -89.86 Mio. EUR |
| -217.81 Mio. EUR |
| -1.22 EUR |
| 85.41 Mio. EUR |
| 26.27 Mio. EUR |
| -76.33 Mio. EUR |
| 2.62 |
| 117.47% |
| -75% |
| - |
| - |
| - |
| - |
| PRECIGEN |
| 30.03.26 |
|